SOPHiA Genetics partners with AstraZeneca on diagnostics
August 05, 2026 | 15:01
SOPHiA Genetics, listed on Nasdaq under ticker SOPH, entered a global collaboration with AstraZeneca to develop, validate and deploy two companion diagnostics supporting precision oncology therapies.
SOPHiA GENETICS names Ross Muken CEO and co-founder Camblong as Chairman nominee
June 11, 2026 | 14:50
SOPHiA GENETICS has confirmed a leadership transition ahead of its 2026 Annual General Meeting, with Ross Muken set to assume the role of CEO effective July 1, 2026, while co-founder Dr. Jurgi Camblong is nominated for election as Chairman.
SOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy Worldwide
April 29, 2025 | 15:45
New collaboration from AACR 2025 aims to make non-invasive cancer testing more accessible on a global scale.
Mobile Version